The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.
Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... In addition to the $240m buyout fee, Bayer has also
Pexa-Vec (pexastimogene devacirepvec) – one of the new class of oncolytic virus therapies (OVT) – didn’t add to the efficacy of therapy when it was added to treatment with
new competition in the market. Bayer and Orion have US approval for their castration-resistant prostate cancer (CRPC) therapy darolutamide, setting up a market clash with Pfizer/Astellas and Johnson &Johnson. ... Bayer says it has also submitted
Sensyne a ‘docking station’ for anonymised NHS patient data analysis. Bayer is to work with health tech and AI specialist Sensyne Health to tap into anonymised real world data, in order ... Bayer has two cardiovascular disease candidates in its
GW Pharma’s Epidyolex also on the recommended list. Bayer’s Vitrakvi has become the first drug in Europe recommended to treat cancer based on a molecular signature, rather than where
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...